Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.876 EUR | +0.96% | +6.41% | +11.97% |
Apr. 10 | Aegon: successful placement of bond issue | CF |
Apr. 10 | Aegon Prices $760 Million Note for General Corporate Purposes | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Its low valuation, with P/E ratio at 8.5 and 6.76 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- The company is one of the best yield companies with high dividend expectations.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.97% | 10.89B | A | ||
+15.94% | 79.51B | B- | ||
+8.42% | 50.22B | B+ | ||
+2.47% | 48.11B | B | ||
+10.21% | 42.2B | B+ | ||
+7.93% | 39.71B | B+ | ||
+20.02% | 37.78B | B | ||
+2.62% | 30.07B | B | ||
-7.27% | 27.56B | B- | ||
-16.43% | 24.71B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AGN Stock
- AGN Stock
- Ratings Aegon N.V.